SARS-CoV-2 Antigen Rapid Qualitative Test Type B

SARS-CoV-2 Antigen Rapid Qualitative Test Type A

FLI-100 FIA Analyzer

The ALL NEW FLI-100 Analyser represents an elevated standard at Biotime, in pursuing simplicity, quality assurance, and data security for healthcare organizations. Designed for quantitative in vitro assay determinations, the Biotime FLI-100 analyser was purposefully built to support immunoassay analysis for a broad range of applications – from biomarker work to infectious disease testing. The analyser’s immunofluorescence technology yields high sensitivity, reliable, and reproducible results for convenient point-of-care diagnostic testing on one device with a small footprint.

HCV Rapid Quantitative Test

Hepatitis C is a liver disease caused by the hepatitis C virus (HCV): the virus can cause both acute and chronic hepatitis, ranging in severity from a mild illness lasting a few weeks to a serious, lifelong illness. Hepatitis C is a major cause of liver cancer.

PROG Rapid Quantitative Test (Chemiluminescence Immunoassay)

PROG Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the Progesterone (PROG) concentration in human serum and plasma that contains heparin /EDTA and other anticoagulants samples, mainly used for auxiliary diagnosis of reproductive hormones diseases.

BIOT-YG-I FIA Analyzer (Fluorescence Immunoassay Analyzer)

BIOT-YG-I is a fluorescence immunoassay system with single channel that measures the quantitative concentration of a targeted analyte in human blood and urine.

SARS-CoV-2 Antigen Rapid Qualitative Test Type A

IL-6 Rapid Quantitative Test (Chemiluminescence Immunoassay)

IL-6 Rapid Quantitative Test (Chemiluminescence Immunoassay) is used for in vitro quantitative detection of the Interleukin-6 (IL-6) concentration in human serum, plasma that contains heparin /EDTA and other anticoagulants and venous whole blood samples, mainly used for auxiliary diagnosis of inflammation diseases.

NGAL Rapid Quantitative Test

NGAL (neutrophil gelatinase-associated lipocalin, lipocalin-2, sidero- calin) is a novel biomarker for diagnosing acute kidney injury (AKI). Under normal conditions NGAL levels are low in urine and plasma Still, they rise sharply from basal levels in response to kidney injury to reach diagnostic levels within a very short time - as much as 24 hours or more before any signiﬁcant rise in serum creatinine.

Solutions

Covid-19 Solution

SARS-CoV-2 Antigen Rapid Test

SARS-CoV-2 Antigen Rapid Qualitative Test Type B